CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Challenges in Multiple Myeloma Therapy in Older and Frail Patients.
Challenges in Multiple Myeloma Therapy in Older and Frail Patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
全球每年诊断出超过 15 万例多发性骨髓瘤（MM），并记录超过 10 万例由该恶性肿瘤导致的死亡。MM 发病率在全球上升，尤其是在高收入国家以及 50 岁以上男性人群中。过去几十年治疗策略进步已改善生存，但相当比例病例仍无法治愈。值得注意的是，约三分之一 MM 患者年龄超过 75 岁，身体适应能力相对较低或存在衰弱。这些患者对各种应激因素更脆弱，对癌症及相关治疗的耐受能力较差。因此，身体适应能力和衰弱状况应纳入 MM 标准评估，并应采用灵活的治疗选择。对 MM 衰弱患者管理研究的审慎综述强烈支持动态评估当前治疗的疗效和不良事件，并结合患者特异性的衰弱状况及合并症进行判断。
Every year, more than 150,000 cases of multiple myeloma (MM) are diagnosed worldwide, and over 100,000 deaths caused by this malignancy are recorded. MM incidence is increasing globally, particularly in high-income countries and in the male population aged 50. While advances in treatment strategies have led to the improvement of survival over the past decades, MM remains incurable in a large percentage of cases.
Importantly, about one-third of patients diagnosed with MM are >75 years old and are characterized by relatively low fitness or frailty. These patients are more vulnerable to stressors and present lower resistance to cancer and related treatments.
Therefore, patients' fitness and frailty should become part of the standard assessment in MM, and flexible therapeutic options should apply. A careful review of studies investigating the management of frail patients with MM strongly supports the use of a dynamic evaluation of effectiveness and adverse events associated with current treatments in the context of patient-specific frailty and co-morbidities.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
